More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
YahooAug 4, 5:30 AM
AI
NEW YORK STOCK EXCHANGE, INC.
ABBV
AbbVie Inc
Updated Aug 4, 2026, 8:05 AM
Last price
$245.10
Day change
-$5.84 (-2.33%)
Open
$251.45
Day range
$244.44 - $256.20
Volume
-
News
Latest company headlines from the cached provider feed.
Updated Aug 4, 2026, 8:05 AM
$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off
The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.
YahooAug 3, 11:14 PM
AbbVie's Growth Now Leans On A Single Molecule
SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.
YahooAug 3, 9:05 PM
Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight
The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to
YahooAug 3, 5:00 PM
Stocks mixed as AstraZeneca merger talk dents FTSE 100
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
YahooAug 3, 4:14 PM
What Are Wall Street Analysts' Target Price for AbbVie Stock?
Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.
YahooAug 3, 4:01 PM